NCT00086632View on ClinicalTrials.gov

Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment

PHASE2TerminatedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 2004

Study Completion Date

December 31, 2007

Conditions
Ovarian Cancer
Interventions
DRUG

oregovomab

Sponsors
All Listed Sponsors
lead

Unither Pharmaceuticals

INDUSTRY